Previous 10 | Next 10 |
home / stock / bayzf / bayzf news
Evotec SE (EVO -16.5%) has regained the rights to eliapixant (BAY1817080) from Bayer (OTCPK:BAYZF) who has decided to discontinue development. The P2X3 antagonist was in phase 2 for several indications: endometriosis, chronic cough, overactive bladder, and neuropathic pain. Eliapixant was par...
The following slide deck was published by Bayer Aktiengesellschaft in conjunction with this event. For further details see: Bayer Aktiengesellschaft (BAYRY) Presents At J.P. Morgan Healthcare Conference
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Despite the first months of the quarter favoring growth, ...
Bayer AG operates in markets with a high potential for growth while occupying a leading position. The company suffered a severe blow due to the purchase of Monsanto and the lawsuits that followed. Considering its financial statements and forecasts, Bayer is fairly valued at the mo...
Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the...
Inflation concerns have started to affect market sentiment, but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market ...
Harris Associates’ 13F portfolio value decreased from $62.80B to $62.77B this quarter. They increased Fiserv, Humana, and Alibaba while decreasing CNH Industrial, Liberty Global, and Automatic Data Processing. The top three positions are Alphabet, Bank of America, and Chart...
BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is expected in Q2 of 2022, with phase 3 study likely to start in 2nd half of 2022. T...
Recursion (RXRX +1.4%) has expanded its partnership with Bayer (OTCPK:BAYZF -0.3%) to now work on more than a dozen programs related to fibrotic disease. The collaboration uses Recursion's inferential search capabilities to gain scientific insights on genetic and pharmacological function...
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG Registered Shares Company Name:
BAYZF Stock Symbol:
OTCMKTS Market:
NORTHAMPTON, MA / ACCESSWIRE / August 29, 2023 / Bayer - As climate change quickens, societal expectations increase and the threat of resistance grows, new crop protection solutions are imperative. Advances in the life sciences and data-driven technologies hold the key to expanding our pipeline ...
Monsanto Must Face Georgia State Jurors in Lawsuit Over Cancer-Causing Roundup Herbicide PR Newswire 11th Circuit opinion finds chemical giant subject to state's warning label laws Nachawati Law Group trial lawyers gearing up for next Roundup cancer trial in Au...
Bayer Runs Out of Appeals at US Supreme Court as Thousands of Cancer Lawsuits Await over Roundup Herbicide PR Newswire Fears Nachawati trial lawyers gearing up for next Roundup cancer trial in August WASHINGTON , June 22, 2022 /PRNewswire/ -- Baye...